GlycoMimetics

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company’s inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.
Company Growth (employees)
Type
Public
HQ
Rockville, US
Founded
2003
Size (employees)
42 (est)+11%
GlycoMimetics was founded in 2003 and is headquartered in Rockville, US

Key People at GlycoMimetics

Brian Hahn

Brian Hahn

Chief Financial Officer
John J. Baldwin

John J. Baldwin

Director
Michael Henos

Michael Henos

Director
Franklin H. Top

Franklin H. Top

Director
William Gust

William Gust

Director
M. James Barrett

M. James Barrett

Chairman of the Board of Directors

GlycoMimetics Office Locations

GlycoMimetics has an office in Rockville
Rockville, US (HQ)
9708 Medical Center Dr

GlycoMimetics Data and Metrics

GlycoMimetics Financial Metrics

GlycoMimetics's revenue was reported to be $18.5 k in FY, 2016 which is a 100% decrease from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

18.5 k

Revenue growth (FY, 2015 - FY, 2016), %

(100%)

Net income (FY, 2016)

(31.8 m)

Market capitalization (26-May-2017)

320.3 m

Closing share price (26-May-2017)

13.9

Cash (31-Dec-2016)

40 m
GlycoMimetics's current market capitalization is $320.3 m.
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Revenue

15 m20.1 m18.5 k

Revenue growth, %

34%(100%)

Operating expense total

26.2 m32.9 m

EBIT

(11.1 m)(12.8 m)

EBIT margin, %

(74%)(64%)

Net Income

(11.1 m)(12.8 m)(31.8 m)
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Cash

55.2 m46.8 m40 m

Inventories

916.2 k441.8 k478.5 k

Current Assets

56.1 m47.2 m40.5 m

PP&E

452.3 k521.4 k1.1 m

Total Assets

57.3 m48.5 m42.4 m

Accounts Payable

874 k564.2 k1.6 m

Current Liabilities

6.5 m7.7 m6.3 m

Additional Paid-in Capital

125.2 m127.6 m154.3 m

Retained Earnings

(74.4 m)(87.2 m)(119 m)

Total Equity

50.8 m40.5 m35.3 m

Financial Leverage

1.1 x1.2 x1.2 x
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Net Income

(11.1 m)(12.8 m)(31.8 m)

Depreciation and Amortization

158.7 k191.5 k190.5 k

Accounts Receivable

(1.9 m)(1.7 m)(1.9 m)

Inventories

1.7 m474.4 k(36.7 k)

Accounts Payable

(270.9 k)(309.8 k)1 m

Cash From Operating Activities

52.9 m(8.4 m)(29.7 m)

Purchases of PP&E

(212.6 k)(268.6 k)(704.2 k)

Cash From Investing Activities

(212.6 k)(268.6 k)(704.2 k)

Cash From Financing Activities

57.4 m114.1 k23.7 m

Income Taxes Paid

80 k80 k80 k
Y, 2016

Financial Leverage

1.2 x

GlycoMimetics Market Value History

GlycoMimetics Company Life and Culture

You may also be interested in